Physician profile
Britney Smith
NPI 1144871260
$6,092.10
in general payments reported to CMS, 2019-2025
27 companies · $2,183 in 2025
The $2,183 reported for 2025 was more than what 96% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $178 · 2022: $763 · 2023: $703 · 2024: $2,265 · 2025: $2,183.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,314 · Travel and Lodging: $659 · Education: $178.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,313.76 |
| Travel and Lodging | $659.23 |
| Education | $178.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $948.05 | 2021-2025 | Airsupra, Fasenra, Breztri |
| Inspire Medical Systems, INC. | $737.52 | 2024-2025 | Inspire |
| Glaxosmithkline, LLC. | $736.02 | 2022-2025 | Trelegy Ellipta, Arexvy, Nucala |
| Boehringer Ingelheim Pharmaceuticals, INC. | $557.73 | 2021-2025 | Ofev, Stiolto Respimat, Spiriva Respimat |
| Electromed, INC. | $431.99 | 2022-2025 | Smartvest |
| Takeda Pharmaceuticals U.S.A., INC. | $417.42 | 2022-2025 | Glassia |
| Grifols USA, LLC | $319.73 | 2021-2025 | Prolastin-C Liquid |
| Genzyme Corporation | $319.32 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $308.26 | 2024-2025 | Dupixent |
| Harmony Biosciences LLC | $240.20 | 2024-2025 | |
| Mylan Specialty L.P. | $206.45 | 2022-2024 | Yupelri |
| Verona Pharma, INC. | $170.07 | 2025 | Ohtuvayre |
| Actelion Pharmaceuticals US, INC. | $133.13 | 2022-2025 | Opsynvi, Opsumit |
| Baxter Healthcare | $80.66 | 2024 | Hillrom - Vest System Model 105 Home Care |
| Sanofi-Aventis U.S. LLC | $78.99 | 2025 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $66.69 | 2021-2025 | Tezspire |
| Insmed, INC. | $60.75 | 2024-2025 | Arikayce |
| Hikma Pharmaceuticals USA | $59.36 | 2024-2025 | Ryaltris |
| 3b Medical, INC. | $43.08 | 2025 | Luna |
| Teva Pharmaceuticals USA, INC. | $30.06 | 2021-2022 | |
| Jazz Pharmaceuticals INC. | $23.19 | 2023 | |
| Avadel Cns Pharmaceuticals, LLC | $22.89 | 2025 | Lumryz |
| United Therapeutics Corporation | $21.51 | 2022 | |
| Genentech USA, INC. | $21.34 | 2024 | Xolair |
| Ani Pharmaceuticals, INC. | $21.15 | 2025 | Purified Cortrophin Gel |
| Advanced Respiratory, INC | $18.78 | 2021 | |
| Sunovion Pharmaceuticals INC. | $17.76 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Britney Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.